AOP 03-007 - ANAHYDRET Study
A single blind, multi-centre, randomised multinational Phase III Study to compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients with Essential Thrombocythaemia
   
Main


Overview
Contact
AOP 03-007 ANAHYDRET STUDY
A single blind, multi-centre, randomised multinational Phase III Study to compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients with Essential Thrombocythaemia

Sponsor:
AOP Orphan Pharmaceuticals AG,
Wilheminenstr.91/II f/B4,A-1160 Vienna - AUSTRIA
Tel: +43 / 1- 503 72 44; Fax: +43 / 1- 503 72 44-5


Overview:

Study Protocol
- Inclusion criteria
- Exclusion criteria
- Randomisation/Patient number allocation
- Study Activities
- Administration of Study Drug
- Duration of study
Appendix I
- Diagnostic Criteria: Essential Thrombocythaemia
- High risk profile
Activity Sheet


For further information please see the Contact Information for your country.